(NASDAQ:EUDA), SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based leading non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced its plans to create an integrated digital health and rewards platform which will use a utility cryptocurrency called QB. The QB […]

(TSX-V:XGC), VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the “Company”) is pleased to announce that it has filed the National Instrument 43-101 (“NI 43-101”) compliant report titled “Technical Report Pico Machay Gold Deposit, Huancavelica Province, Peru” effective November 18th, 2025 and dated December 4th, 2025 (the

(TSX:PEA),(TSX:CVVY), Not For Distribution to United States News Wire Services or Dissemination in United States CALGARY, Alberta, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cavvy Energy Ltd. (“Cavvy” or the “Company”) (TSX:CVVY) is pleased to release 2026 guidance, highlighted by accelerated debt reduction targeting $50 million and an increase in net operating income of over 25%

(TASE:KMDA.TA),(NASDAQ:KMDA), Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA(R), its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDA Kamada Reiterates its 2025 Full-Year Revenue

(NASDAQ:PCVX), Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive (PCV21) and Prevnar 20 (PCV20), the Current Standards of Care Company Expects to Report Topline Safety, Tolerability and

(TSX:OR),(NYSE:OR), MONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) — OR Royalties Inc. (the “Company” or “OR Royalties“) (OR: TSX & NYSE) is pleased to announce that the Toronto Stock Exchange (the “TSX“) has approved the Company's notice of intention to make a normal course issuer bid (the “NCIB Program“). Under the terms of the NCIB Program,

(NasdaqGM:OCUL), Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approvals which has the potential to shorten the review timeline for AXPAXLI If

(TSX-V:CRD), TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Copper Road Resources Inc. (TSX-V: CRD) (“Copper Road” or the “Company”) is pleased to announce that it has signed a non-binding Letter of Intent (“LOI”) to option 174 cell claims (within 495 provincial grid cells) with a spatial exploration extent of approximately 10,232 hectares (“ha”), including 13

(NASDAQ:AGIO), CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the supplemental New Drug Application (sNDA) for mitapivat for

(CNSX:YMC.CN),(CNSX:YMC),(Boerse Frankfurt – Freiverkehr:E770),(OTC US:YMMCF),(Other OTC:YMMCF), VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company“) is pleased to announce results from the last two holes of the 2025 drill program at its 100% owned 7,000-hectare Birch Copper-Gold Project (“Birch”), located 65